Immediate and long-term outcomes of percutaneous transcatheter pulmonary valve implantation by Fiszer, Roland et al.
Address for correspondence: Roland Fiszer, MD, Department of Congenital Heart Diseases and Pediatric Cardiology,  
Silesian Center For Heart Diseases, Silesian University of Medicine, ul. Marii Curie-Skłodowskiej 9, 41–800 Zabrze,  
Poland, tel/fax: +48 32 271 34 01, e-mail: rfiszer@gumed.edu.pl
Received: 27.09.2016 Accepted: 05.01.2017
INTERVENTIONAL CARDIOLOGY
Cardiology Journal 
2017, Vol. 24, No. 6, 604–611
DOI: 10.5603/CJ.a2017.0023 
Copyright © 2017 Via Medica
ISSN 1897–5593
604 www.cardiologyjournal.org
ORIGINAL ARTICLE
Immediate and long-term outcomes of percutaneous 
transcatheter pulmonary valve implantation
Roland Fiszer1, Paweł Dryżek2, Małgorzata Szkutnik1,  
Sebastian Góreczny2, Alexandra Krawczuk2, Jadwiga Moll2,  
Tomasz Moszura2, Szymon Pawlak3, Jacek Białkowski1
1Department of Congenital Heart Diseases and Pediatric Cardiology, Silesian Center  
for Heart Diseases, Silesian University of Medicine, Zabrze, Poland 
2Pediatric Cardiology Department of Polish Mother’s Memorial Hospital, Łódź, Poland 
3Pediatric Cardiac Surgery, Heart Failure and Transplantation Department,  
Silesian Center for Heart Diseases, Zabrze, Poland
Abstract
Background: Transcutaneous pulmonary valve replacement (TPVR) has become an alternative to 
heart surgery for patients after previous right ventricular outflow tract (RVOT) or pulmonary artery 
(PA) surgical interventions. The objective was to present immediate and long-term outcomes of trans-
cutaneous pulmonary valve replacement. 
Methods: Between 06/2009 and 06/2016, 46 patients underwent TPVR. Initial diagnoses included 
tetralogy of Fallot, common arterial trunk, transposition of great arteries post Rastelli correction, left 
ventricle outflow obstruction after Ross operation, pulmonary atresia, and isolated dysplastic pulmonary 
valve stenosis. Thirty eight (78%) patients had previously implanted conduits in the pulmonary position, 
the rest had either RVOT patch reconstruction (n = 6; 13%) or biological valve implantation (n = 2; 
4%). They presented primarily with pulmonary stenosis (n = 18; 39%) or regurgitation (n = 28; 60%). 
Results: All procedures were successful — 44 Melody and 2 Edwards-Sapien valves were implanted. 
Before each procedure exclusion of potential coronary compression and RVOT prestenting was performed. 
Significant RVOT systolic gradient reduction (from 35.3 ± 19.5 to 13.5 ± 7.1 mm Hg; p < 0.001)  
and decrease of right to left ventricle systolic pressure ratio from 0.58 ± 0.18 to mean 0.37 ± 0.1  
(p < 0.001) was achieved. Also, in every patient PA-RVOT competence was restored, with minor in-
competence in only a few patients. Post procedure follow-up ranged from 2 to 86 (mean 35.2) months. 
Follow-up fluoroscopy or chest X-ray revealed 6 stent fractures (2 stent defragmentation — with only  
1 significant valve stenosis).
Conclusions: Transcutaneous pulmonary valve replacement is a safe procedure with encouraging 
results, it also enables deferring surgical reintervention in the majority of patients. (Cardiol J 2017; 24, 
6: 604–611)
Key words: pulmonary valve, transcatheter valve implantation, congenital heart disease
Introduction
Transcutaneous pulmonary valve replacement 
(TPVR) has become a promising alternative to open 
heart surgery for patients after previous right ven-
tricular outflow tract (RVOT) or pulmonary valve 
and pulmonary artery (PA) surgical interventions. 
Initially, the treatment was limited to a select group 
of patients with a dysfunction (stenosis and/or 
insufficiency) of a previously implanted surgical 
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graft. Mainly patients after surgery for tetralogy 
of Fallot (TOF) with homograft, pulmonary atresia, 
common arterial trunk, and patients after Ross 
and Rastelli operations were candidates for this 
method of treatment. Those patients usually had 
undergone several surgical interventions. The gen-
eral indications for pulmonary valve replacement 
are well defined [1, 2] and rely on right ventricular 
(RV) enlargement and functional compromise, 
along with pulmonary artery stenosis and/or re-
gurgitation. Both are preferentially presented on 
magnetic resonance imaging [3]. The number of 
patients undergoing transcatheter pulmonary valve 
implantation has been steadily increasing. Since 
2000, when Bonhoeffer et al. [4] preformed the 
first human implantation, more than ten thousand 
procedures have been performed with favorable 
results. In the last few years the indications for 
TPVR expanded and the method of treatment has 
included some postsurgical patients after TOF 
repair with pericardial patch or biological valve in 
the pulmonary position. Moreover, an increasing 
number of publications on TPVR in non-standard 
pulmonary positions have been published [5, 6]. 
Currently, there are two commercially available 
types of percutaneous implantable pulmonary valves 
on the European market, the more popular Melody 
valve (Medtronic Minneapolis, Minnesota, USA) 
and the less used Edwards-Sapien valve (Edwards 
Lifesciences LLC, Irvine, California, USA) [7, 8].
The aim of this study is to present 7 years 
of experience in percutaneous pulmonary valve 
implantation in patients with surgically placed 
conduits, or after RVOT patch repair performed 
at two reference centers in Poland.
Methods
Between 06/2009 and 06/2016, 46 patients 
had undergone TPVR in two tertiary centers. 
All met criteria to restore proper RV-PA function 
(RV diastolic volume index > 140 mL/m2, RV 
end-systolic volume index > 80 mL/m2 or pulmo-
nary regurgitation fraction > 40 % as well as RV 
function impairment — ejection fraction < 40% 
or RV-PA gradient > 40 mm Hg). There were 
27 (58%) males and 19 (41%) females aged mean 
18.3 ± 6.9 years. Their weight ranged from 28 to 
98, mean 55.5 ± 15.8 kg. Initial diagnoses included 
TOF (n = 18; 39%), common arterial trunk (n = 9; 
16%), transposition of great arteries post Rastelli 
surgery (n = 8; 17%), aortic stenosis and left ven-
tricular outflow tract obstruction post Ross-like op-
erations (n = 5; 10%), pulmonary atresia (n = 3; 6%), 
and isolated pulmonary valve stenosis (n = 2; 4%). 
Thirty eight (82.6%) patients had had previously 
implanted conduits in the pulmonary position and 
presented clinically with significant graft narrowing 
and/or regurgitation. In the majority (n = 35; 92%) 
a homograft was used to reconstruct the RVOT, 
with the remaining received a contegra graft (n = 3; 
8%). Eight patients had either a patch reconstruc-
tion (n = 6) or biological valve implantation (n = 2). 
In 17 (34 %) stenosis (right ventricle — PA gradient 
> 40 mm) and in 29 (60%) regurgitation, was the 
major indication for TPVR. Among patients with 
predominant stenosis the RV-PA invasive systolic 
pressure gradient was mean 52.7 ± 17.9 mm Hg, 
whereas in patients with predominant regurgitation 
the mean gradient was 24 ± 9.9 mm Hg. Six patients 
with TOF had pericardial patch correction and pre-
sented with pulmonary regurgitation. One patient 
had a biological stentless valve (Freestyle 23 mm) 
implanted in the pulmonary position, who shortly 
after surgery developed severe stenosis with an 
invasive gradient of 46 mm Hg. Another patient had 
TOF corrected with the application of the cor-matrix 
valve subsequently with a gradient of 52 mm Hg. 
Three TOF patients (two treated with homograft 
and one with cor-matrix valve) had a primary absent 
pulmonary valve with a grossly enlarged PA (one 
with left pulmonary artery agenesis). Similarly, two 
patients after homograft insertion had pulmonary 
artery agenesis, one left-sided and one right-sided.
All patients had diagnostic images including 
transthoracic echocardiogram, contrast computed 
tomography, magnetic resonance and/or diagnostic 
cardiac catheterization; in order to define stenosis 
and regurgitation and to determine anatomy for 
TPVR. All procedures were performed according to 
previously described methods [2, 5, 8–10]. General 
anesthesia with endotracheal intubation, antibiotic 
prophylaxis and intravenous heparin (100 IU/kg) 
were used in all patients. Diagnostic right heart 
catheterization was performed with angiography to 
define the RVOT physiology and anatomy. Potential 
coronary compression was excluded with simulta-
neous balloon inflation in the RVOT and selective 
coronary angiography or aortic root angiography. 
In adherence to the recommendations [7–9], all 
patients underwent routine prestenting to create 
a landing zone for subsequent TPVR. Two differ-
ent types of implantable valves were used in the 
study. Melody valve — bovine jugular venous valve 
sutured on 8-zig, 34 mm Cheatham Platinum (CP) 
stent available in two diameters; expandable to 
20 mm and to 22 mm. The device was delivered on 
18, 20, or 22 mm Ensemble delivery system. The 
606 www.cardiologyjournal.org
Cardiology Journal 2017, Vol. 24, No. 6
Edwards-Sapien valve — bovine pericardial valve 
mounted within stainless steel stent is available 
in diameters of 23, 26 and recently in 29 mm [8]. 
In 8 patients valve implantation was postponed 
for 2–3 months after prestenting in order to allow 
stent fixation. The Melody valve was mounted 
on a 18, 20 or 22 mm delivery system. Edwards-
Sapien valves were delivered on the Retroflex 3 
delivery system (Figs. 1–4). Additional dilatation, 
with Mullins balloon (22 mm), was performed in 
Figure 1. Pulmonary angiography in left anterior oblique 
(LAO) 90 projection. Homograft narrowing and severe 
pulmonary regurgitation.
Figure 3. Left anterior oblique 90. Pulmonary valve 
expanded in presented right ventricular outflow tract.
Figure 2. Left anterior oblique 90. Right ventricular out-
flow tract prestenting.
Figure 4. Pulmonary angiography left anterior oblique 
90. Competent valve implanted in pulmonary position.
15 patients with > 25 mm Hg gradients across the 
valve. Hemostasis was achieved with compression 
or Z-suture. Patient follow-up included clinical 
examination, electrocardiogram, transthoracic 
echocardiography and chest X- ray or fluoroscopy.
Ethical considerations 
No ethical committee agreement was required. 
Each patient signed written consent for the pro-
cedure.
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Statistical analysis
Shapiro–Wilk test was used for testing normal-
ity. Depending on statistical distribution, numerical 
data were shown by mean and standard deviation, 
then compared with t-Student test for paired 
samples or Wilcoxon signed-rank test for in-time 
comparisons. The difference between groups was 
compared using t-Student for independent samples 
or the Mann–Whitney U test. Binary data were 
compared with the Yates corrected c2 test. Kaplan– 
–Meier curves were used to assess free-from-fail-
ure survival. P < 0.05 was considered significant. 
Results
During the study all 46 patients underwent 
successful TPVR procedures, 44 patients with 
Melody valve and 2 patients with Edwards-Sapien 
valve. Most procedures were performed using 
the standard technique, from femoral access. In 
2 patients with bilateral femoral vein occlusion 
the jugular approach was used, 1 patient required 
trans-atrial valve implantation. One with greatly 
enlarged RVOT, required the hybrid procedure with 
surgical narrowing initially, and then percutaneous 
valve implantation. All patients had routine pre-
stenting — the majority of which 38 (82%) during 
the same procedure. Five patients with TOF and 
pericardial patch had severely dilated RVOT — pre-
stenting was performed in order to prevent further 
dilatation and to create the landing zone for TPVR 
3 months before implantation. Also, 3 patients with 
full homograft had a prestenting procedure initially, 
and 3 months later, valve implantation. In one of 
those patients there was significant narrowing of 
the RVOT after double stent implantation, and 
immediately preceding the Melody valve another 
stent was implanted. One patient had the land-
ing zone created in a telescopic manner utilizing 
the previously implanted stent in the left PA. In 
another patient with graft narrowing close to the 
bifurcation — the first stent was implanted par-
tially into the right PA, stent struts were opened 
into the left PA and the next was implanted below. 
Prestenting procedures were performed with 
AndraStent in 20 (43%) patients, bare CP stent 
in 14 (30%), covered CP stent in 10 (21%) and 
IntraStent in 2 (4%) patients. Eight patients with 
severe homograft stenosis required multiple (2 or 
3) stents due to significant stent recoil after balloon 
deflation. The 22 mm delivery system was utilized 
in 29 patients, 20 mm in 13 patients and 18 mm in 
2 patients. Two patients received a 23 mm Ed-
wards-Sapien valve (decision operator dependent). 
TPVR was successful in all cases. The systolic 
pressure gradient decreased from mean 35.3 ± 19.5 
mm Hg to mean 13.5 ± 7.1 mm Hg (p < 0.001). The 
gradient reduction was particularly spectacular in 
patients with predominant stenosis. In this group 
(n = 17) the implantation gradient decreased from 
mean 52.7 ± 17.9 mm Hg to mean 15.2 ± 7 mm 
Hg after the procedure. In the group with domi-
nant regurgitation the gradient dropped from mean 
24 ± 9.9 mm Hg to mean 12.5 ± 7.1 mm Hg. The 
RV/LV systolic pressure ratio before the implanta-
tion mean 0.58 ± 0.18 decreased to mean 0.37 ± 0.1 
(p < 0.001); from mean 0.7 ± 0.18 to mean 0.37 ± 
± 0.08 among patients with predominant stenosis, 
and from mean 0.5 ± 0.12 to mean 0.37 ± 0.11 in 
those with significant regurgitation. 
Selected demographic, procedural and follow-up 
data in both groups of patients are presented in 
Table 1. Initial systolic RV-PA gradient and RV/LV ratio 
before the procedure were significantly higher in 
patients with predominant stenosis (p < 0.001).
One patient with critical homograft stenosis 
required serial dilatation with increasing balloon 
sizes followed by CP stent implantation and finally 
Melody valve insertion 3 months later. In angiog-
raphy trivial post-procedural pulmonary regurgita-
tion was observed in 7 patients after Melody valve 
implantation. Mild regurgitation was seen in both 
patients after Edwards-Sapien valve and one after 
Melody valve placement. Fifteen (32%) patients 
required valve dilation with 22 mm high pressure 
Mullins balloon. No major procedural complications 
were observed. In 1 patient with TOF and absent 
pulmonary valve with enormously dilated PA 
treated with homograft, the stent used in the prest-
enting procedure dislocated distally. The stent was 
placed in the right PA and another one was success-
fully deployed. In 1 patient the tip of the guide wire 
was caught in the peripheral PA branch and could 
not be retrieved. The tip of the wire was cut off and 
left with no further consequences for the patient 
in follow-up. Mean post procedure follow-up was 
35.2 ± 28.9 months. On first transthoracic echocar-
diography after the TPVR, 15 patients presented 
with trivial/mild regurgitation. During the follow-
up no increase of pulmonary regurgitation was ob-
served. RVOT peak gradient pre-discharge ranged 
from 7 to 47, mean 27 ± 9.1 mm Hg. After a median 
of 35.2 months following the intervention the gradi-
ent ranged from 14 to 80, mean 28 ± 13.9 mm Hg. 
Stent integrity was assessed in 36 (78%) patients 
either with fluoroscopy (n = 20) or with chest X-ray 
(n = 16). Eight patients had the procedure per-
formed less than 1 year before the end of follow-up 
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and had no fluoro/X-ray checkup. In 1 patient 
fluoroscopy was abandoned due to pregnancy and 
1 patient was lost from the follow-up. We found stent 
fracture in 4 and stent disintegrity in 2 patients with 
part of the stent embolized to the peripheral PA. 
Albeit there was no serious valve dysfunction in 
any patient with stent fracture or disintegrity. Only 
1 patient presented with increase in RVOT peak 
gradient to 80 mm Hg and is regarded as suitable 
for revalvulation. Follow-up data was used to build a 
Kaplan-Meier curve assessing free-from-failure with 
combined end-point: stent breakage and/or device 
dysfunction survival (Fig. 5).
Discussion
Surgical treatment of RVOT has been per-
formed successfully by homograft insertion for 
many decades. Eventually however, a significant 
number of patients develop dysfunction often 
requiring re-intervention [11, 12]. The patients 
are teenagers or young adults, often after several 
previous surgical interventions. TPVR has become 
an alternative method of treatment for those with 
residual stenosis or regurgitation [2, 10, 13–15]. 
Critically, this treatment is also possible for pa-
tients after TOF patch surgery, a large group of 
patients with congenital heart diseases. Patients 
at risk of coronary artery compression were ex-
cluded from the procedure [16–18]. Standard indi-
cations for TPVR require circumferential conduit 
in the pulmonary position. It was considered from 
experience that there were 35 patients with ho-
mografts, all were treated in the standard TPVR 
manner. According to recommendations, all had 
Table 1. Some demographic procedural and follow-up data.
Data Overall  
(n = 46)
Predominant  
stenosis
Predominant  
regurgitation
P
Tetralogy of Fallot patients 18 6 12 0.739
Other heart diseases 28 11 17 0.979
Initial surgery 
With conduit 40 17 23 0.380
Without conduit 6 0 6 0.068
Initial systolic RV-PA gradient [mm Hg] 35.2 ± 19.5 55.18 ± 14.98 23.55 ± 9.98 < 0.001
Initial RV-Ao pressure ratio 0.58 ± 0.18 0.71 ± 0.19 0.50 ± 0.12 < 0.001
Systolic RV-PA gradient post procedure [mm Hg] 13.54 ± 7.08 15.77 ± 6.77 12.24 ± 7.04 0.085
Systolic RV-Ao ratio post procedure 0.37 ± 0.09 0.38 ± 0.07 0.37 ± 0.11 0.829
Stents used in prestenting [no. of patients] 56 25 31
Complications 2 0 2 0.524
Follow up [months] 35.18 ± 28.87 38.88 ± 30.67 33.01 ± 28.09 0.682
Outcome
Peak RV-PA gradient in echocardiogram  
on discharge [mm Hg]
27 ± 9.12 28 ± 9.62 27.30 ± 9.75 0.812
Stent integrity assessment (stent fracture) 36 (6) 11 (3) 25 (3) 0.343
Peak RV-PA gradient in echocardiogram  
in last follow up [mm Hg]
28 ± 13.89 28 ± 17.38 28.51 ± 10.79 0.902
RV — right ventricle; PA — pulmonary artery; Ao — aorta
Figure 5. Kaplan–Meier curve depicting the probabil-
ity of outcome — freedom from event (stent fracture 
and valve dysfunction) after transcutaneous pulmonary 
valve implantation.
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prestenting performed before TPVR. Prestenting 
decreases the number of stent fractures observed 
in follow-up [8, 19]. However, some authors [20] 
point out possible valve compression in significant 
homograft calcifications even with standard pre-
senting. Eight patients in this study with tortuous 
conduits positioned close to the chest wall or with 
a tight stenosis, required multiple stents to create 
an unobstructed outflow tract. This approach may 
prevent the recoil phenomenon and subsequent 
valve compression. Those patients sometimes 
present increased RVOT gradient in follow-up and 
require valve replacement due to unacceptable re-
sidual stenosis. In order to prevent this situation, 
it was decided to separate prestenting and TPVR 
in 3 patient with homograft and tight stenosis. 
One patient underwent another stent implantation 
(3 months later) directly before the Melody valve 
was implanted. Also a few patients who required 
multiple balloon predilations of the RV-PA conduit 
to enable safe and effective prestenting.
Currently, a circumferential graft in the pul-
monary position is not required for TPVR [14, 15, 
17]. In the present study, we had 6 patients with 
the RVOT reconstructed with a pericardial patch. 
This technique is used much more often for TOF 
correction than graft implantation. TPVR in such 
patients is possible, however, a staged approach 
with stent implantation followed by valve implan-
tation 3 months later is preferred. This allows 
stent ingrowth, creating a stabile landing zone for 
subsequent valve placement. The delayed valve 
implantation in such patients is recommended by 
several authors [7, 8, 21]. One patient with severely 
dilated RVOT had surgical narrowing of the RVOT 
and then percutaneous valve implantation. This ap-
proach, to restore proper RV-PA function was done 
without cardio pulmonary by-pass. Many authors 
indicate pulmonary outflow diameter in patients 
with patch as the major limitation for TPVR [7, 8, 
15, 17]. The final decision was based on outflow 
tract balloon measurement during cardiac cath-
eterization. For the Melody valve, stabile position 
of the balloon inflated in the RVOT with maximal 
diameter of the waist ≤ 25 mm are mandatory. One 
of the patched patients previously underwent a left 
PA stent implantation. The prestenting procedure 
was performed in a telescopic manner, with a left 
PA stent serving as an anchor for the entire landing 
zone (another stent in RVOT). 
For prestenting mainly bare metal stents 
were used in 36 patients. In 10 cases, patients 
with severe calcification CP covered stents were 
used as the initial stent. According to the literature 
significant and particularly circumferential homo-
graft calcification is a risk factor for RV-PA conduit 
rupture and subsequent bleeding. The best way 
to avoid this often deadly complication is to use 
a covered stent. There were some patients with 
unfavorable PA anatomy (absent pulmonary valve 
with large main pulmonary artery, and absent left 
or right PA). Although technically more demanding, 
TPVR in these patients was successful. Chessa et 
al. [22] reported valve implantation in the lumen 
of a single PA with this anatomy. This modifica-
tion was not made, as these patients had a full 
homograft implanted and the TPVR procedure was 
performed in a standard manner. One significant 
complication was noted in this group of patients 
— stent migration was subsequently secured in 
the peripheral RPA branch.
TPVR may also be very useful in patients after 
failed surgical PA valve replacement. In the present 
study 2 patients had biological valves (stentless 
Freestyle 23 and core-matrix valve). In the first 
patient, one and half years after surgery, the gradi-
ent had increased to 49 mm Hg and in the second 
patient to 52 mm Hg. One stent was applied in 
a prestenting procedure in 1 patient and 2 stents 
in the second patient. In both cases a Melody valve 
was implanted with no complications and a good 
final result. TPVR not only prevents RV volume 
overload by establishing a barrier for flow reversal 
but, it also diminishes homograft narrowing and 
RV pressure. Significant gradient reduction was 
expected and observed particularly in patients with 
predominant stenosis. In all patients, pulmonary 
regurgitation was reduced to none or minor after 
the procedure — similarly to reported in literature 
[5, 7, 8, 14]. To date, follow-up of this study ranges 
from 2 to 86 months. There was a 100% survival 
rate over this time. In only 1 patient, an increase 
in the implanted valve gradient was recorded in 
transthoracic echocardiography. No increase of 
implanted pulmonary valve regurgitation was ob-
served in follow-up, indicating good function over 
this period of time. Usually, valve dysfunction in 
the short term is caused by infective endocardi-
tis. Despite an increasing number of publications 
concerning this problem, no such complications 
were observed [23–25]. However, similar to the 
literature, there were 6 cases of broken stents — 
5 stents used for prestenting (1 covered CP stent, 
1 AndraStent and 3 bare CP stents) and 1 stent used 
as Melody valve scaffolding. In two of those cases 
stent desintegration defragmentation was found, 
with part of the stent fixed to the peripheral PA 
branch. In both cases no significant valve dysfunc-
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tion was noted, although one had a peak gradient 
80 mm Hg, and was qualified for percutaneous re-
valvulation. The number of “silent” stent fractures 
in this series is similar to literature [9, 17, 19]. In 
this experience some patients had fluoroscopy and 
some chest XR to look for fractures — the reason 
was a difference in follow-up protocol at the two 
centers. However Butera et al. [17] recommends 
fluoroscopy as a better tool to discover silent stent 
fractures — and yearly exams should be done. The 
risk factors for fractures are well known; implanta-
tion in a native narrowed RVOT, lack of calcifica-
tions and homograft recoil [17, 19, 26]. The best 
known way to avoid the problem is prestenting 
with multiple stents. In the present study there 
were 2 patients who had recoil in homograft nar-
rowing. One patient required the implantation of 
3 stents prior to completing the TPVR procedure, 
another patient received an additional third stent, 
3 months after the initial prestenting. In the case 
of severe dysfunction of the previously implanted 
valve, according to some authors, patients may be 
treated with percutaneous revalvulation, and in 
others, surgery may be necessary.
Limitation of the study
The group of patients was collected from two 
centers with some differences in implantation 
details and follow-up protocols. Although most 
of the patients had Melody valves implanted, two 
received Edwards valves. The material and con-
struction of the different valves renders the group 
of patients not homogeneous. 
Conclusions
Patients with indication for percutaneous pul-
monary valve implantation require careful RVOT 
assessment and sometimes, prestenting with 
multiple stents. TPVR was a safe procedure, with 
encouraging short- and mid-term results; avoiding 
the need for additional surgery.
Conflict of interest: None declared 
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